蓝帆医疗
(002382)
| 流通市值：58.58亿 | | | 总市值：59.02亿 |
| 流通股本：10.00亿 | | | 总股本：10.07亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,780,551,449.68 | 1,477,911,477.13 | 6,253,168,236.58 | 4,654,357,096.34 |
| 营业收入 | 2,780,551,449.68 | 1,477,911,477.13 | 6,253,168,236.58 | 4,654,357,096.34 |
| 二、营业总成本 | 2,960,366,551.91 | 1,508,152,236.39 | 6,620,497,143.37 | 4,865,860,745.45 |
| 营业成本 | 2,381,801,341.21 | 1,224,199,609.93 | 5,222,701,975.08 | 3,855,177,720.39 |
| 税金及附加 | 23,710,145.16 | 12,143,832.56 | 42,138,967.02 | 32,131,109.21 |
| 销售费用 | 214,511,264.44 | 91,890,359.91 | 465,976,276.08 | 327,176,779.71 |
| 管理费用 | 148,604,568.21 | 69,509,328.6 | 348,509,007.38 | 240,582,619.09 |
| 研发费用 | 122,304,096.36 | 68,114,361 | 341,915,007.55 | 245,358,824.93 |
| 财务费用 | 69,435,136.53 | 42,294,744.39 | 199,255,910.26 | 165,433,692.12 |
| 其中:利息费用 | 137,452,699.13 | 70,545,959.16 | 278,979,702.23 | 206,191,854.31 |
| 其中:利息收入 | 14,202,391.71 | 6,962,972.45 | 30,384,815.97 | 20,810,832.04 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 6,523,442.42 | 127,910,871.77 | 6,541,868.72 | -6,407.82 |
| 加:投资收益 | 5,592,656.84 | 1,798,623.76 | -7,474,359.78 | -7,721,768.26 |
| 资产处置收益 | -372,425.04 | 106,916.49 | -839,222.11 | -360,058.44 |
| 资产减值损失(新) | -68,260,025.29 | -45,865,732.57 | -53,735,642.88 | -15,345,677.01 |
| 信用减值损失(新) | 2,674,632.21 | 3,877,232.87 | -24,706,929.91 | -15,644,217.19 |
| 其他收益 | 41,978,303.89 | 13,905,108.26 | 30,979,097.13 | 22,020,165.74 |
| 四、营业利润 | -191,678,517.2 | 71,492,261.32 | -416,564,095.62 | -228,561,612.09 |
| 加:营业外收入 | 2,266,552.94 | 394,778.73 | 21,298,978.61 | 18,764,827.6 |
| 减:营业外支出 | 2,690,037.16 | 883,092.6 | 6,338,794.4 | 4,525,038.97 |
| 五、利润总额 | -192,102,001.42 | 71,003,947.45 | -401,603,911.41 | -214,321,823.46 |
| 减:所得税费用 | -49,283,013.74 | -11,529,996.09 | 63,317,316.2 | 12,601,948.52 |
| 六、净利润 | -142,818,987.68 | 82,533,943.54 | -464,921,227.61 | -226,923,771.98 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -142,818,987.68 | 82,533,943.54 | -464,921,227.61 | -226,923,771.98 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -134,779,268.14 | 77,022,348.52 | -445,608,865.62 | -219,822,842.84 |
| 少数股东损益 | -8,039,719.54 | 5,511,595.02 | -19,312,361.99 | -7,100,929.14 |
| 扣除非经常损益后的净利润 | -209,757,631.99 | -60,790,742.49 | -479,857,621.27 | -249,135,906.18 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.13 | 0.08 | -0.44 | -0.22 |
| (二)稀释每股收益 | -0.13 | 0.08 | -0.44 | -0.22 |
| 八、其他综合收益 | 26,574,975.36 | 2,412,969.11 | 27,426,379.65 | -32,979,291.84 |
| 归属于母公司股东的其他综合收益 | 23,247,327.47 | 2,556,983.3 | 22,518,852.99 | -25,647,369.57 |
| 九、综合收益总额 | -116,244,012.32 | 84,946,912.65 | -437,494,847.96 | -259,903,063.82 |
| 归属于母公司股东的综合收益总额 | -111,531,940.67 | 79,579,331.82 | -423,090,012.63 | -245,470,212.41 |
| 归属于少数股东的综合收益总额 | -4,712,071.65 | 5,367,580.83 | -14,404,835.33 | -14,432,851.41 |
| 公告日期 | 2025-08-30 | 2025-04-29 | 2025-04-29 | 2024-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |